Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma (CC6)

A Multinational, Multicenter, Open-label, Single-arm, Phase II Study of G17DT Immunogen in Combination With Irinotecan in Metastatic Colorectal Carcinoma Refractory to Previous Irinotecan-based Chemotherapy.

This study was designed to evaluate the ability for G17DT to slow or arrest tumor growth in patients with refractory colon cancer who had been previously treated with an Irinotecan-based chemotherapy.

Study Overview

• Status: Completed
• Conditions: Colorectal Cancer
• Intervention / Treatment: Biological: G17DT-Irinotecan

• Study Type: Interventional
• Enrollment (Actual): 161
• Phase: Phase 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Have histologically confirmed cancer of the colon or rectum or both and objective evidence of distant metastases
• Have measurable disease
• Have previously been treated with an irinotecan based chemotherapy
• Have progressive metastatic disease after an irinotecan containing chemotherapy regimen (alone or in combination) for metastatic colorectal cancer
• Be at least 18 years of age

• Have laboratory data as specified below:

  • Aspartate aminotransferase (AST) and ALT less than 2.5 times upper limit of normal
  • Bilirubin less than 1.5 mg/dL (SI units, 25.65 mol/L)
  • Creatinine less than 1.5 mg/dL (SI units, 132 mol/L)
  • White blood cell (WBC) count greater than 3,000/mm3
  • Platelets greater than 100,000/mm3
  • Hemoglobin more than 9.5 g/dL (SI units, 5.9 mol/L)
  • International normalized ratio of prothrombin time less than 1.2, and activated partial thromboplastin time no more than 5 seconds above normal limits
• Have a life expectancy of at least 3 months
• Have a KPS score of 70 or greater
• Use contraceptive methods, if sexually active
• Have the ability to understand the requirements of the study, to provide written informed consent, agree to abide by the study restrictions, and agree to return for the required assessments

Exclusion Criteria:

• Be pregnant or nursing
• Have only symptomatic locally recurrent colorectal cancer
• Have had any active cancer in addition to metastatic colorectal cancer within the last 5 years except curatively treated nonmelanomatous skin cancer
• Have received any prior anticancer immunotherapy
• Have central nervous system metastasis, whether treated or not
• Have bone metastases as sole manifestation of metastatic colorectal cancer
• Have received chemotherapy within the previous 21 days
• Have had major surgery within 21 days
• Have immunodeficiency (primary or acquired)
• Have undergone bone marrow transplantation within the last year
• Require chronic administration of corticosteroids; inhaled corticosteroids for asthma and chronic obstructive pulmonary disease are allowed
• Use in the past 30 days or concomitant use of immunosuppressants, including systemic (i.e., oral or injected) corticosteroids
• Have participated in any clinical trial involving conventional or investigational drugs or devices within 21 days before G17DT irinotecan administration
• Have contraindication to irinotecan based therapy
• Have hypersensitivity to diphtheria toxoid
• Use in the past 14 days or chronic concomitant use of proton pump inhibitors
• Have uncontrolled serious cardiovascular or metabolic disease or any other uncontrolled serious medical or psychiatric illness
• Have any condition that is likely to detrimentally affect regular follow up

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: G17DT-Irinotecan; 500µg dose of G17DT intramuscular injection in combination with 125 mg/m^2 intravenous infusion of Irinotecan over 90 minutes.	Biological: G17DT-Irinotecan; 500µg dose of G17DT intramuscular injection in combination with 125 mg/m^2 intravenous infusion of Irinotecan over 90 minutes.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tumor response	Evaluate the effect of G17DT-Irinotecan combination therapy on tumor response assessed by magnetic resonance imaging or computed tomography.	up to 12 months
Survival time	The vital status of patients was monitored until death or end of the study.	up to 12 months
Number of Patients with Serious and Non-Serious Adverse Events	Adverse events, defined as any event involving adverse reactions, illnesses with onset during the study, or exacerbations of pre-existing illnesses, were assessed at each visit.	Up to 12 months

Collaborators and Investigators

• Sponsor: Cancer Advances Inc.

Study record dates

Study Major Dates

• Study Start: March 1, 2001
• Primary Completion (Actual): December 1, 2002

Study Registration Dates

• First Submitted: April 16, 2014
• First Submitted That Met QC Criteria: April 17, 2014
• First Posted (Estimate): April 21, 2014

Study Record Updates

• Last Update Posted (Estimate): April 21, 2014
• Last Update Submitted That Met QC Criteria: April 17, 2014
• Last Verified: January 1, 2014

More Information

Terms related to this study

• Keywords: Colorectal Cancer; irinotecan; G17DT
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colorectal Neoplasms; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Topoisomerase Inhibitors; Topoisomerase I Inhibitors; Irinotecan
• Other Study ID Numbers: CC6